

ASX RELEASE

10 January 2025

### Release of Shares from Voluntary Escrow

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) confirms in accordance with ASX Listing Rule 3.10A that 781,250 ordinary shares issued on 19 July 2024 as a fee for services of a corporate advisor will be released from voluntary escrow on 19 January 2025.

This ASX announcement is authorised for release by the Company Secretary.

- End -

**Investor Contact:**

Dr Chris Burns  
Chief Executive Officer  
[chris@ampliatx.com](mailto:chris@ampliatx.com)

**Media Contact:**

HACK Director, Haley Chartres  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 423 139 163

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit [www.ampliatx.com](http://www.ampliatx.com) and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/ampliatx).